Kyverna Therapeutics Unveils Strategic Priorities and Anticipated Milestones for 2025 at J.P. Morgan Healthcare Conference
Kyverna Therapeutics, Inc., a leading biotechnology company focusing on autoimmune diseases, revealed its strategic ...
FOX40 News26d
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
Jan. 6, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna ... its 2025 strategic priorities and key milestones during a presentation on Monday, January 13, 2025, at 5:15 p.m. PST.
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc.(KYTX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want ...
KELOLAND News19d
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna ... its 2025 strategic priorities and key milestones during a presentation that will be made by Chief Executive Officer, Warner ...
Mena FN2d
Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
On June 14, 2024, Kyverna provided an update on its lupus nephritis drug, KYV-101, and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite ...
bovnews5d
Kyverna Therapeutics Inc (KYTX) Stock Rated Buy by UBS
Kyverna Therapeutics Inc (KYTX) stock saw a modest uptick, ending the day at $3.6 which represents a slight increase of $0.21 or 6.19% from the prior close of $3.39. The stock opened at $3.37 and ...